NCT06138028View on ClinicalTrials.gov

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Metastatic Esophageal Squamous Cell Carcinoma
Interventions
DRUG

TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）

TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.

Trial Locations (2)

266042

RECRUITING

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao

RECRUITING

Qingdao Central Hospital, Qingdao

All Listed Sponsors
lead

Qingdao Central Hospital

OTHER